Navigation Links
Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
Date:11/5/2009

ed the second course of re-treatment data from a Phase 2b study (15002) of TRU-015 for rheumatoid arthritis (RA) at the American College of Rheumatology (ACR) Annual Meeting in Oct. 2009. Data continue to demonstrate that repeat administration of TRU-015 is well-tolerated and improves the signs and symptoms of RA as measured by the ACR rates. At 24 weeks after the second re-treatment course, subjects in the group that had received 800 mg of TRU-015 of the initial treatment achieved ACR 20, 50 and 70 response rates of 72%, 39% and 21%, respectively. Results were similar to the response rates seen 24 weeks after the first re-treatment of the same cohort as presented at the European League Against Rheumatism (EULAR) Annual Meeting in June 2009 (70%, 40% and 23%, respectively). Trubion has now administered more than 1,300 doses of TRU-015 over a period of four and a half years.
  • In Sept. 2009, patient enrollment was completed in the second Phase 2b study (2203) of TRU-015 for RA.
  • 2009 Financial Guidance

    The company has revised its 2009 guidance after taking into account its collaboration agreement with Facet. As a result, the company has lowered its anticipated annual burn rate from $30 million-$35 million to $0-$5 million. No changes have been made to anticipated revenues for 2009. The revised guidance is as follows:

    • Reiterate 2009 revenues of approximately $15 million to $20 million; and
    • Revised 2009 operating cash requirements are now expected to be approximately $0 to $5 million.

    This guidance does not include any additional cash receipts associated with potential new partnerships.

    Conference Call Details

    Trubion will host a conference call and webcast to discuss its third quarter and nine months ended Sept. 30, 2009, financial results and provide an update on business activities. The call will be held Nov. 5 at 2 p.m. Pacific Time, 5 p.m. Easter
    '/>"/>

    SOURCE Trubion Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Trubion Announces Upcoming Presentation at 8th Annual BIO Investor Forum
    2. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
    3. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
    4. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
    5. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
    6. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
    7. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
    8. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
    9. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
    10. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
    11. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2015)... PLEASANTON, Calif. , July 28, 2015 /PRNewswire/ ... tremendous burden that pressure ulcers place on the ... are a leading threat to modern quality healthcare. ... Human Services, Agency for Healthcare Research and Quality ... system more than $11 billion a year. The ...
    (Date:7/28/2015)...  Today, Sekisui Diagnostics announces the launch of the ... with a broad menu of high quality SEKURE reagents, ... office or hospital laboratory. The SK500 ... ISE, 72 patient sample on-board capability, minimizes the use ... ISE) to meet the testing needs of small-to-moderate volume ...
    (Date:7/28/2015)... 28, 2015 Voalte, the leader in ... in purpose-built wireless communications, today announced that Bay ... 104-bed acute-care facility in Webster, Texas ... One™ solution on Spectralink PIVOT™ purpose-built smartphones for ... Voalte a member of its AIMS Partner Program ...
    Breaking Medicine Technology:Impact of Pressure Ulcers on Patient Care: Leaf Healthcare Releases White Paper on the Healthcare Burden of Pressure Ulcers 2Impact of Pressure Ulcers on Patient Care: Leaf Healthcare Releases White Paper on the Healthcare Burden of Pressure Ulcers 3Sekisui Diagnostics Announces Launch of SK500 Clinical Chemistry System for US Laboratories 2Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 2Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 3
    ... NEWTON, Mass. , Aug. 5 Microfluidics International Corporation (OTC Bulletin Board: ... on Tuesday, August 10, 2010 , at 8:30am ET . , ... (Logo: http://photos.prnewswire.com/prnh/20090811/NE59652LOGO ) , , ... ) , , , ...
    ... 5 Cornerstone Therapeutics Inc. (Nasdaq: ... specialty pharmaceutical company focused on acquiring, developing and commercializing ... today announced that its product candidate CRTX-067 is an ... mg hydrocodone polistirex suspension product that will be a ...
    Cached Medicine Technology:Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010 2Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010 3Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010 4Cornerstone Therapeutics Announces Development of Generic for Tussionex® 2Cornerstone Therapeutics Announces Development of Generic for Tussionex® 3
    (Date:7/28/2015)... ... July 28, 2015 , ... Jordan Valley Medical Center ... The Guidelines®-Stroke Gold Plus Award for implementing specific quality improvement measures outline by ... The Get With The Guidelines-Stroke program recognizes hospitals that demonstrate at least 85 ...
    (Date:7/28/2015)... ... ... A skin cancer screening program offered by the American Society for Dermatologic ... to make the world a better place.” , The Choose Skin Health program has ... Association Executives. Power of A recognizes organizations annually that “distinguish themselves with innovative, effective ...
    (Date:7/28/2015)... ... 2015 , ... The Triumph Modular, Redefining Modular™ site offers ... library, floor plans, educational blog and wide use of imagery. The Design Build ... valuable links to useful reports by industry experts. Comments are welcomed and encouraged. ...
    (Date:7/28/2015)... ... July 28, 2015 , ... A new study published ... who continued methadone maintenance treatment (MMT) during incarceration versus those subjected to a ... opiate use (1) and more likely to require hospitalization or emergency treatment (2) ...
    (Date:7/28/2015)... ... July 28, 2015 , ... The Denver Foundation and ... Reframed and Exhibited,” a photographic and narrative exploration of African American giving, which ... Points neighborhood. , Denver is one of only ten cities to host “The ...
    Breaking Medicine News(10 mins):Health News:Jordan Valley Medical Center and Jordan Valley Medical Center West Valley Campus Receive Stroke Award 2Health News:Jordan Valley Medical Center and Jordan Valley Medical Center West Valley Campus Receive Stroke Award 3Health News:ASDS Skin Cancer Program Honored 2Health News:ASDS Skin Cancer Program Honored 3Health News:Triumph Modular Launches Refreshed Modular Building Industry Website 2Health News:Novus Medical Detox Center Analyzes Methadone Study Findings and Implications for Opiate Abuse Treatment 2Health News:Novus Medical Detox Center Analyzes Methadone Study Findings and Implications for Opiate Abuse Treatment 3Health News:Novus Medical Detox Center Analyzes Methadone Study Findings and Implications for Opiate Abuse Treatment 4Health News:"The Soul of Philanthropy Reframed and Exhibited” Comes to Denver 2
    ... Ltd. has found that H5N1 virus replikin peak gene ... and Israel indicate that a new replikin cycle has ... the previous cycle identified by the company. Although several ... in replikin count, a feature of each of the ...
    ... awaking from terminal coma, 25 year illness reversed ... BiomagScience.com. Testing showing how the cells respond ... resolution of unusually acute or chronically ill conditions ... Why Biomagnetism is an amazing science that affords ...
    ... Plan Provides Affordable Medical Insurance, Making Urgent Care Available to More ... ... Mesa, AZ (PRWEB) June 27, 2008 -- NextCare ( www.nextcare.com ... the implementation of a new affordable medical insurance plan, CareForToday. The ...
    ... relative of maize, teosinte, does not look very promising as ... domesticated one, and the grains are surrounded by hard fruitcases ... Mexico, and, around 10,000 years ago, mutations in the wild ... looking for some starch in their diets. Saved seed ...
    ... offers good fit to childhood immunization ... providing protection with fewer shots -, SWIFTWATER, Pa., ... Group, announced today that its Pentacel(R),Diphtheria and Tetanus Toxoids ... (Tetanus Toxoid,Conjugate) Vaccine will be included in the federal ...
    ... Awareness Month an Ideal Time to Take Stock of Supplemental Insurance Protection ... ... , a leading provider of supplemental insurance, encourages consumers to use Safety ... the right supplemental insurance protection in place to meet their ...
    Cached Medicine News:Health News:H5N1 Virus Replikin Gene Counts Indicate a New More Virulent Influenza Cycle Has Begun 2Health News:Baby's Blindness Resolved, Nerves in Knee Regenerated and Other Unusual Complimentary Therapies from BiomagScience 2Health News:Baby's Blindness Resolved, Nerves in Knee Regenerated and Other Unusual Complimentary Therapies from BiomagScience 3Health News:Baby's Blindness Resolved, Nerves in Knee Regenerated and Other Unusual Complimentary Therapies from BiomagScience 4Health News:Baby's Blindness Resolved, Nerves in Knee Regenerated and Other Unusual Complimentary Therapies from BiomagScience 5Health News:Urgent Care Provider NextCare Introduces CareForToday Medical Insurance Plan 2Health News:To branch or not to branch 2Health News:To branch or not to branch 3Health News:Federal Advisory Committee Votes to Include Newly Licensed Pentacel(R) Vaccine in Vaccines for Children Program 2Health News:Federal Advisory Committee Votes to Include Newly Licensed Pentacel(R) Vaccine in Vaccines for Children Program 3Health News:Federal Advisory Committee Votes to Include Newly Licensed Pentacel(R) Vaccine in Vaccines for Children Program 4Health News:Federal Advisory Committee Votes to Include Newly Licensed Pentacel(R) Vaccine in Vaccines for Children Program 5Health News:Combined Insurance: Consider Supplemental Accident Insurance and Disability Insurance During Safety Awareness Month 2Health News:Combined Insurance: Consider Supplemental Accident Insurance and Disability Insurance During Safety Awareness Month 3Health News:Combined Insurance: Consider Supplemental Accident Insurance and Disability Insurance During Safety Awareness Month 4Health News:Combined Insurance: Consider Supplemental Accident Insurance and Disability Insurance During Safety Awareness Month 5
    Clear plastic sleeve envelopes a plastic suction catheter. Sleeve slides over exudate to reduce potential clinician contact....
    Kit includes whistle tip catheter with two eyes and control vent, 2 vinyl gloves, and pop-up solution container in peel- open package....
    Extra Long Gentle Vactrol® Connector., ,Indications For Usage: ,Removal of secretions from respiratory tract....
    D-Line Coude' Suction Catheter., ,Indications For Usage: , Removal of secretions from respiratory tract , For ease and greater assurance of entering and suctioning the left bronchus ...
    Medicine Products: